Pillar Biosciences Announces U.S. Food and Drug Administration Acceptance of Premarket Approval (PMA) Supplement Application for Pan-cancer oncoReveal™ CDx
– PMA supplement will further expand oncoReveal™ Dx indication/label to include ability to detect additional eight cancer types ˗ Company continues to execute on its strategy to bring highly accurate and sensitive NGS cancer diagnostics to enable localized testing NATICK, Mass. – July 19, 2022 – (BUSINESS WIRE) – Pillar Biosciences, the leader in Decision […]